Method for treating membranous nephropathy with taci-fc fusion protein
AssigneeRemegen Co., Ltd.
InventorsXiangdong YANG, Ling GUO, Dengren LI, Jianmin FANG, Wenxiang WANG
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a drug, a dosage scheme, an administration interval, and an administration mode for treating membranous nephropathy with a TACI-Fc fusion protein. Results show that the TACI-Fc fusion protein provided by the present disclosure shows relatively good clinical curative effect and good safety in the process of treating a patient with membranous nephropathy.
Claims18
A method of treating membranous nephropathy, comprising administering a therapeutically effective amount of a TACI-Fc fusion protein to a patient with membranous nephropathy, wherein the TACI-Fc fusion protein comprises:
- (i) a TACI extracellular region or a fragment thereof binding to Blys and/or APRIL;
- and
- (ii) a fragment of human immunoglobulin constant region.
Dependencies are inferred from the claim text.